These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 23711387

  • 21. Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression.
    Menendez JA, Mehmi I, Lupu R.
    J Clin Oncol; 2006 Aug 10; 24(23):3735-46. PubMed ID: 16847284
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. A pathway-based approach for identifying biomarkers of tumor progression to trastuzumab-resistant breast cancer.
    Nam S, Chang HR, Jung HR, Gim Y, Kim NY, Grailhe R, Seo HR, Park HS, Balch C, Lee J, Park I, Jung SY, Jeong KC, Powis G, Liang H, Lee ES, Ro J, Kim YH.
    Cancer Lett; 2015 Jan 28; 356(2 Pt B):880-90. PubMed ID: 25449779
    [Abstract] [Full Text] [Related]

  • 24. TIMP-1 overexpression does not affect sensitivity to HER2-targeting drugs in the HER2-gene-amplified SK-BR-3 human breast cancer cell line.
    Deng X, Fogh L, Lademann U, Jensen V, Stenvang J, Yang H, Brünner N, Schrohl AS.
    Tumour Biol; 2013 Apr 28; 34(2):1161-70. PubMed ID: 23334956
    [Abstract] [Full Text] [Related]

  • 25. EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance.
    Dua R, Zhang J, Nhonthachit P, Penuel E, Petropoulos C, Parry G.
    Breast Cancer Res Treat; 2010 Aug 28; 122(3):685-97. PubMed ID: 19859802
    [Abstract] [Full Text] [Related]

  • 26. Cullin7 enhances resistance to trastuzumab therapy in Her2 positive breast cancer via degrading IRS-1 and downregulating IGFBP-3 to activate the PI3K/AKT pathway.
    Qiu N, He YF, Zhang SM, Zhan YT, Han GD, Jiang M, He WX, Zhou J, Liang HL, Ao X, Xia HM, Li J, Yang YY, He ZM, Zou ZZ, Li HS.
    Cancer Lett; 2019 Nov 01; 464():25-36. PubMed ID: 31461670
    [Abstract] [Full Text] [Related]

  • 27. Her2/neu induces all-trans retinoic acid (ATRA) resistance in breast cancer cells.
    Tari AM, Lim SJ, Hung MC, Esteva FJ, Lopez-Berestein G.
    Oncogene; 2002 Aug 08; 21(34):5224-32. PubMed ID: 12149644
    [Abstract] [Full Text] [Related]

  • 28. Growth differentiation factor 15 (GDF15)-mediated HER2 phosphorylation reduces trastuzumab sensitivity of HER2-overexpressing breast cancer cells.
    Joshi JP, Brown NE, Griner SE, Nahta R.
    Biochem Pharmacol; 2011 Nov 01; 82(9):1090-9. PubMed ID: 21803025
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. MicroRNA-7 inhibits multiple oncogenic pathways to suppress HER2Δ16 mediated breast tumorigenesis and reverse trastuzumab resistance.
    Huynh FC, Jones FE.
    PLoS One; 2014 Nov 01; 9(12):e114419. PubMed ID: 25532106
    [Abstract] [Full Text] [Related]

  • 32. Calpain4 is required for activation of HER2 in breast cancer cells exposed to trastuzumab and its suppression decreases survival and enhances response.
    Kulkarni S, Saju L, Farver C, Tubbs R.
    Int J Cancer; 2012 Nov 15; 131(10):2420-32. PubMed ID: 22377768
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
    Vazquez-Martin A, Colomer R, Brunet J, Menendez JA.
    Int J Oncol; 2007 Oct 15; 31(4):769-76. PubMed ID: 17786307
    [Abstract] [Full Text] [Related]

  • 37. Breast cancer stem cells are involved in Trastuzumab resistance through the HER2 modulation in 3D culture.
    Rodríguez CE, Berardi DE, Abrigo M, Todaro LB, Bal de Kier Joffé ED, Fiszman GL.
    J Cell Biochem; 2018 Feb 15; 119(2):1381-1391. PubMed ID: 28722778
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Modulation of MicroRNA-194 and cell migration by HER2-targeting trastuzumab in breast cancer.
    Le XF, Almeida MI, Mao W, Spizzo R, Rossi S, Nicoloso MS, Zhang S, Wu Y, Calin GA, Bast RC.
    PLoS One; 2012 Feb 15; 7(7):e41170. PubMed ID: 22829924
    [Abstract] [Full Text] [Related]

  • 40. Trastuzumab-resistant HER2-driven breast cancer cells are sensitive to epigallocatechin-3 gallate.
    Eddy SF, Kane SE, Sonenshein GE.
    Cancer Res; 2007 Oct 01; 67(19):9018-23. PubMed ID: 17909003
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.